Argenx
ARGX
#435
Rank
A$79.83 B
Marketcap
A$1,270
Share price
-0.55%
Change (1 day)
1.56%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): A$23.66

According to Argenx 's latest financial reports the company's current EPS (TTM) is A$22.48. In 2025 the company made an earnings per share (EPS) of A$29.97 an increase over its 2024 EPS that were of A$19.79.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$23.66-21.05%
2025A$29.9751.44%
2024A$19.79-369.77%
2023A-$7.34-60.46%
2022A-$18.5663.33%
2021A-$11.36-40.37%
2020A-$19.05183.47%
2019A-$6.72123.09%
2018A-$3.0154.93%
2017A-$1.9414.07%
2016A-$1.7013.05%
2015A-$1.51-36.34%
2014A-$2.37209.04%
2013A-$0.77-33.99%
2012A-$1.16185.59%
2011A-$0.41